Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies

CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies In Vitro Research Overview CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cA

By Recovery & Performance Peptides Editorial Team

CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies

CJC-1295 GHRH-R Research: Growth Hormone Axis Regulation Studies

In Vitro Research Overview

CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. The compound represents a modified analogue of growth hormone-releasing hormone (GHRH) engineered for extended stability and receptor interaction studies.

Research applications focus on understanding pituitary somatotroph cell responses, receptor binding kinetics, and intracellular signalling cascade activation. Laboratory investigations utilise established cell lines including CHO cells transfected with human GHRH receptors, primary pituitary cell cultures, and immortalised somatotroph models for pharmacological characterisation.

Receptor Pharmacology and Mechanism of Action

GHRH Receptor Binding Characteristics

CJC-1295 acts via GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Competitive radioligand binding assays demonstrate nanomolar affinity for the GHRH receptor, with binding constants typically ranging from 0.5-2.0 nM in transfected cell systems. The compound exhibits selectivity for GHRH receptors over other related class B GPCRs including VIP, PACAP, and glucagon receptors.

Saturation binding experiments reveal specific, high-affinity interaction with GHRH receptor sites. Scatchard analysis indicates single-site binding kinetics with Hill coefficients approximating unity, suggesting non-cooperative binding behaviour. Competition studies using native GHRH(1-29) confirm receptor specificity and demonstrate comparable binding affinity profiles.

Signal Transduction Pathways

Upon receptor binding, CJC-1295 activates Gs protein-coupled adenylyl cyclase pathways, resulting in elevated intracellular cyclic adenosine monophosphate (cAMP) concentrations. Real-time cAMP accumulation assays show dose-dependent responses with EC50 values typically in the 0.1-1.0 nM range in responsive cell models.

Protein kinase A (PKA) activation follows cAMP elevation, as demonstrated through phosphorylation of downstream substrates including CREB (cAMP response element-binding protein). Western blot analysis reveals time-dependent CREB phosphorylation at Ser133 residues, indicating functional coupling to transcriptional regulatory mechanisms.

Albumin Binding Modifications

DAC Conjugation Effects

The drug affinity complex (DAC) modification involves lysine conjugation that facilitates albumin binding, extending compound stability in cell culture systems. Surface plasmon resonance studies demonstrate high-affinity albumin interaction with dissociation constants in the micromolar range. This modification does not significantly impair GHRH receptor binding affinity based on competitive binding analyses.

Albumin-bound fraction studies using equilibrium dialysis techniques show extensive protein binding (>95%) in serum-containing culture media. Despite high albumin affinity, receptor activation remains robust, suggesting effective dissociation kinetics allow productive receptor engagement.

Cell Model Applications

Somatotroph Cell Systems

Primary rat anterior pituitary cell cultures serve as physiologically relevant models for CJC-1295 receptor pharmacology studies. These heterogeneous cultures contain native somatotroph populations expressing endogenous GHRH receptors. Flow cytometry analysis confirms somatotroph identity through growth hormone immunostaining.

Immortalised GH3 and GH4C1 cell lines provide reproducible experimental platforms for mechanistic studies. These rat pituitary-derived cells maintain GHRH receptor expression and cAMP responsiveness, enabling standardised assay protocols for compound evaluation.

Transfected Cell Models

CHO-K1 cells stably transfected with human GHRH receptor cDNA offer homogeneous receptor expression for detailed pharmacological characterisation. Receptor density quantification through radioligand saturation binding typically yields 50,000-200,000 binding sites per cell, providing robust assay sensitivity.

HEK293 transient transfection systems allow rapid screening of receptor variants and mutants to probe structure-activity relationships. Luciferase reporter constructs driven by cAMP response elements enable high-throughput functional assessment of signalling pathway activation.

Research Summary

CJC-1295 represents a valuable research tool for investigating GHRH receptor pharmacology and growth hormone regulatory mechanisms in vitro. The compound demonstrates high-affinity, selective GHRH receptor binding with potent activation of Gs/cAMP/PKA signalling cascades. DAC albumin-binding modifications extend compound stability without compromising receptor interaction. Established cell models including primary pituitary cultures, immortalised cell lines, and transfected systems provide complementary platforms for comprehensive pharmacological characterisation. These in vitro systems enable detailed investigation of receptor binding kinetics, signal transduction mechanisms, and downstream cellular responses relevant to growth hormone axis regulation.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

CJC-1295 Recovery Dosing Protocols — What Research Applications Use

Clinical trials and laboratory research protocols for CJC-1295 recovery applications typically dose between 30–60 mcg/kg body weight, administered subcutaneously once or twice weekly. A 70 kg subject would receive approximately 2–4 mg per injection. This range produces mean GH elevations of 2–5 fold baseline with IGF-1 increases of 1.5–2.5 fold, sustained for 5–7 days post-injection. Dosing above 60 mcg/kg does not produce proportional IGF-1 increases. The relationship plateaus due to hepatic IGF-1 synthesis capacity limits. Twice-weekly protocols (e.g., Monday/Thursday) maintain more stable IGF-1 levels throughout the week compared to once-weekly dosing, which shows a peak at 48–72 hours and gradual decline by day 6–7. For recovery-focused studies where consistent anabolic signaling matters more than peak amplitude, the twice-weekly structure outperforms single weekly injections. Injection timing relative to training or injury does not significantly alter outcomes. IGF-1 elevation is systemic and prolonged, so acute timing is less critical than maintaining dosing consistency. Reconstitution follows standard peptide protocols: lyophilised CJC-1295 is mixed with bacteriostatic water at a ratio that produces the desired concentration (commonly 2 mg/mL for ease of dosing). Once reconstituted, the peptide must be refrigerated at 2–8°C and used within 28 days. Beyond that window, protein aggregation and oxidation degrade potency even if the solution appears clear. Unreconstituted…
STORAGE

The Art of Reconstitution: Ensuring Stability

Reconstitution is often the first step where the potential for CJC-1295 degradation reconstituted truly begins. Doing it correctly is an art and a science. Here’s a step-by-step guide we advocate: Gather Your Materials: You'll need your lyophilized CJC-1295, a sterile syringe, a sterile needle, and your chosen sterile solvent (e.g., Bacteriostatic Reconstitution Water (bac)). Make sure everything is clean and ready. Determine Dilution: Calculate the precise amount of solvent needed to achieve your desired concentration. Accuracy here prevents waste and ensures reproducible experimental conditions. Careful Injection: Slowly inject the solvent down the side of the vial, allowing it to gently run down and mix with the peptide powder. Avoid directly squirting the solvent onto the powder, as this can cause foaming and aggregation. That's a mistake we've seen many times. Gentle Dissolution: Do not shake vigorously. Instead, gently swirl the vial to allow the peptide to dissolve. If it doesn't dissolve immediately, let it sit for a few minutes at room temperature, then swirl again. Patience is key here. Rapid agitation can cause shear stress, which contributes to CJC-1295 degradation reconstituted. Immediate Storage: Once fully dissolved, immediately store the reconstituted peptide under appropriate conditions (refrigeration or freezing, protected from light). Don't leave it sitting out, even for a short while. This methodical approach, while seemingly simple, makes a world of diff…
02

Question drills

Open a question for its connected answer.

01What If I Accidentally Added Too Much Water During Reconstitution?+

Measure the exact volume you added using a calibrated syringe, then recalculate your concentration. If you added 2.3mL to a 2mg vial instead of 2mL, your concentration is 2mg ÷ 2.3mL = 0.87mg/mL. Each 10 IU tick now contains 87mcg instead of 100mcg. Adjust your tick count upward to compensate: for a 200mcg dose, draw 23 ticks instead of 20. Do not discard the vial. Diluted peptide is still viable; you're just drawing a larger volume per dose. Mark the vial with the actual concentration to avoid confusion on subsequent draws.

SOURCE / realpeptides.co ↗
02What If Your Protocol Requires Minimal Secondary Hormone Activation?+

Tesamorelin or sermorelin are the cleanest choices. Both are pure GHRH analogues that bind exclusively to pituitary GHRH receptors without activating ghrelin, cortisol, or prolactin pathways. Administer tesamorelin 2mg daily or sermorelin 200–300mcg 2–3 times daily. Clinical trials show these compounds elevate GH and IGF-1 without measurable changes in cortisol, ACTH, or prolactin across 26-week study periods. Ipamorelin also avoids cortisol/prolactin activation despite being a ghrelin agonist, but tesamorelin carries FDA approval as additional validation.

SOURCE / realpeptides.co ↗
03What If SubQ Injection Causes a Visible Lump at the Site?+

A transient subcutaneous nodule lasting 15–45 minutes post-injection is normal and indicates proper depot formation in adipose tissue. The lump represents the injected volume (typically 0.5–1.0mL) dispersing through interstitial space before capillary absorption. If the lump persists beyond 2 hours, hardens, or becomes painful, it may indicate improper reconstitution (aggregated peptide fragments), injection into fibrotic tissue from repeated use of the same site, or inadvertent intradermal (not subcutaneous) placement. Rotate sites, ensure bacteriostatic water reconstitution follows proper technique, and verify needle depth. 4–6mm at a 45-degree angle for most body compositions.

SOURCE / realpeptides.co ↗
04What If My IGF-1 Was 190 ng/mL at 4 Weeks But Dropped to 155 ng/mL at 12 Weeks?+

This indicates tachyphylaxis. Pituitary GH secretagogue receptors have downregulated in response to chronic stimulation, reducing biological response despite continued dosing. Cycle off CJC-1295 entirely for 4–6 weeks to allow receptor resensitization, then restart at the original dose. IGF-1 should return to the 4-week peak (190 ng/mL range) within 4 weeks of restarting if receptor sensitivity has been restored.

SOURCE / realpeptides.co ↗
05What If Cortisol Is Chronically Elevated Above 18 µg/dL?+

CJC-1295 efficacy will be blunted until cortisol is managed. Hepatic GH receptor expression is cortisol-sensitive. Chronic elevation downregulates receptor density, preventing IGF-1 synthesis even when GH pulses are extended. Address the root cause: sleep restriction, chronic caloric deficit, or unmanaged psychological stress. In research settings, subjects with morning cortisol above 20 µg/dL showed 40–50% lower IGF-1 responses compared to baseline-matched controls, despite identical CJC-1295 dosing. Cortisol isn't a secondary variable. It's the master regulator of hepatic GH sensitivity.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

CJC-1295 GHRH-R Research: GH Axis Signalling and Pituitary Cell Model Studies

CJC-1295 GHRH-R Research: GH Axis Signalling and Pituitary Cell Model Studies CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action CJC-1295 acts via GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. The compound exhibits selective binding interactions at the growth hormone-releasing hormone receptor, a member of the secretin family of G-protein coupled receptors. In vitro binding studies demonstrate high affinity interactions with GHRH-R expressed in transfected cell lines. The drug affinity complex (DAC) modification involves lysine substitution at position 2, enabling covalent albumin binding through maleimidopropionic acid linkage. This structural modification significantly alters pharmacokinetic parameters in cell culture media containing albumin, extending compound stability and prolonging receptor engagement duration in time-course assays. Receptor Binding Characteristics Competitive binding assays using radiolabeled GHRH demonstrate CJC-1295 binding affinity (Ki) values in the nanomolar range at recombinant GHRH receptors. Saturation binding experiments reveal reversible, specific interactions with receptor sites, displaying typical GPCR binding kinetics. Scatchard plot analysis confirms single-site binding behaviour consistent with GHRH-R selectivity. Structure-activity relationship studies indicate critical amino acid residues for receptor recognition, particularly the N-terminal domain responsible for receptor activation. The C-terminal DAC modification does not significantly impact binding affinity but substantially influences compound-albumin interactions in serum-containing media. Signalling Pathway Activation cAMP-PKA Cascade Engagement GHRH-R activation by CJC-1295 triggers Gs protein-mediated adenylyl cyclase stimulation, resulting in intracellular cAMP accumulation. Dose-response curves in CHO-K1 cells stably expressing human GHRH-R demonstrate EC50 values for cAMP production in the low nanomolar range. Time-course studies reveal sustained cAMP elevation compared to native GHRH, attributed to enhanced receptor occupancy duration. Protein kinase A (PKA) activation occurs downstream of cAMP elevation, measured through PKA substrate phosphorylation assays. Western blot analysis shows enhanced CREB phosphorylation at Ser133, indicating successful signal transduction through the canonical GHRH-R pathway. Transcriptional Response Mechanisms Luciferase reporter assays utilising CRE-driven constructs demonstrate transcriptional activation following CJC-1295 treatment in GHRH-R expressing cell lines. Quantitative PCR analysis reveals upregulation of immediate early genes including c-fos and egr-1, consistent with CREB-mediated transcriptional responses. Gene expression profiling in pituitary adenoma cell lines (GH3, GH4C1) shows dose-dependent increases in growth hormone mRNA levels, measured through real-time PCR. These transcriptional effects correlate with cAMP response element activation, confirming pathway specificity. Cell Model Applications Primary Pituitary Cell Cultures Primary rat anterior pituitary cell cultures serve as physiologically relevant models for CJC-1295 mechanism studies. Dispersed pituitary cells maintain GHRH-R expression and demonstrate robust cAMP responses to compound treatment. Flow cytometry analysis reveals somatotroph-specific responses, identified through growth hormone immunostaining. Calcium imaging studies in primary somatotrophs show secondary calcium mobilisation following PKA activation, indicating complex intracellular signalling networks. These calcium responses correlate with growth hormone secretion patterns measured through enzyme-linked immunosorbent assays. Immortalised Cell Line Models GH3 pituitary adenoma cells provide standardised models for receptor pharmacology studies, expressing endogenous GHRH-R at physiologically relevant levels. Concentration-response relationships for cAMP production demonstrate reproducible pharmacological profiles across experimental replicates. Transfected HEK293 cell systems enable controlled receptor expression studies, allowing precise characterisation of binding kinetics and signalling parameters. These heterologous expression systems facilitate structure-function relationship investigations through site-directed mutagenesis approaches. Enzyme Kinetics and Metabolic Stability In vitro stability assays using liver microsome preparations demonstrate enhanced metabolic resistance compared to native GHRH. The DAC modification confers protection against enzymatic degradation, measured through LC-MS/MS analysis of compound integrity over time. Enzymatic binding studies reveal albumin association kinetics, with kon and koff rates determined through surface plasmon resonance. These binding parameters directly influence compound availability for receptor interactions in serum-containing experimental conditions. Research Summary CJC-1295 represents a modified GHRH analogue with enhanced pharmacological properties for in vitro research applications. The compound demonstrates selective GHRH-R binding, robust cAMP-PKA pathway activation, and sustained signalling responses in multiple cell model systems. The DAC modification provides unique experimental advantages through albumin binding, enabling extended compound exposure studies. These pharmacological characteristics make CJC-1295 a valuable research tool for investigating growth hormone axis signalling mechanisms in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

RESEARCH

CJC-1295 GHRH-R Research: Pharmacology Profile and Cell Model Studies

CJC-1295 GHRH-R Research: Pharmacology Profile and Cell Model Studies CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action CJC-1295 acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor. The compound exhibits enhanced receptor binding characteristics compared to native GHRH through structural modifications that improve stability and binding kinetics. In vitro receptor binding studies demonstrate CJC-1295's high affinity interaction with GHRH-R, with binding constants indicating strong receptor engagement across multiple cell model systems. The peptide's mechanism involves activation of the Gs protein pathway, leading to adenylyl cyclase stimulation and subsequent cyclic adenosine monophosphate (cAMP) elevation. This cascade activates protein kinase A (PKA), which phosphorylates downstream transcription factors including CREB (cAMP response element-binding protein). Laboratory studies using fluorescence-based cAMP assays consistently demonstrate dose-dependent increases in intracellular cAMP levels following CJC-1295 treatment in GHRH-R-expressing cell lines. Drug Affinity Complex (DAC) Modification The drug affinity complex (DAC) component represents a critical pharmacological feature of CJC-1295. This modification involves conjugation with a maleimidopropionic acid linker that facilitates albumin binding through covalent interaction with cysteine residues. In vitro albumin binding studies reveal high-affinity interactions, with association constants indicating strong protein conjugation under physiological conditions. Cell-based pharmacokinetic modelling demonstrates that DAC modification significantly alters the compound's distribution and availability profiles in culture medium containing albumin. Binding kinetics studies show rapid albumin association followed by slower dissociation rates, creating a reservoir effect that maintains sustained receptor activation over extended timeframes in continuous perfusion cell culture systems. Cell Model Systems and Assay Development Primary Cell Models Research applications utilize various cell model systems expressing endogenous GHRH-R. Primary pituitary adenocyte cultures serve as physiologically relevant models for investigating CJC-1295's receptor pharmacology. These systems demonstrate robust cAMP responses to CJC-1295 stimulation, with EC50 values typically ranging in the nanomolar concentration range across multiple independent cell preparations. Immortalized cell lines transfected with human GHRH-R provide standardized platforms for reproducible pharmacological characterization. HEK293 and CHO cell systems expressing recombinant GHRH-R enable detailed receptor binding studies, competition assays, and downstream signalling pathway analysis under controlled experimental conditions. Signalling Pathway Analysis Advanced cell-based assays reveal CJC-1295's effects on multiple downstream signalling cascades beyond the primary Gs/cAMP pathway. Calcium mobilization studies in certain cell models indicate potential cross-talk with calcium-dependent signalling mechanisms. Phosphoproteomic analysis demonstrates PKA-mediated phosphorylation of numerous substrate proteins involved in transcriptional regulation and metabolic enzyme activity. Real-time PCR analysis of GHRH-R-expressing cell cultures treated with CJC-1295 reveals time-dependent changes in gene expression profiles. Transcriptional targets include immediate early genes and factors involved in growth hormone synthesis and secretion pathways, demonstrating functional coupling between receptor activation and downstream cellular responses. Comparative Receptor Pharmacology Structure-activity relationship studies comparing CJC-1295 with native GHRH and other analogues reveal distinct pharmacological profiles. Receptor binding competition assays demonstrate CJC-1295's enhanced binding affinity, with improved receptor residence time compared to unmodified peptides. Functional selectivity studies indicate preserved efficacy at GHRH-R while maintaining selectivity over related class B GPCRs. Enzyme kinetics analysis of adenylyl cyclase activation shows CJC-1295 produces sustained enzymatic activity compared to transient responses observed with native GHRH. This prolonged activation profile correlates with extended cAMP elevation and downstream pathway engagement in cell-based functional assays. Research Summary In vitro pharmacological characterization establishes CJC-1295 as a potent GHRH-R agonist with unique albumin-binding properties through DAC modification. Cell model studies demonstrate nanomolar binding affinity, robust Gs/cAMP/PKA pathway activation, and sustained receptor engagement. The compound's pharmacological profile in various cell-based assay systems supports its utility as a research tool for investigating GHRH-R signalling mechanisms and downstream cellular responses in controlled laboratory environments. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 (No DAC) vs. CJC-1295 with DAC: A Critical Comparison

Understanding the fundamental differences between CJC-1295 (no DAC) and CJC-1295 with DAC is absolutely crucial for any researcher venturing into CJC-1295 sustained GH therapy. Wh…

Comparison

A Comparison: Approaches to Combat Muscle Wasting

Let's take a moment to compare some of the general approaches researchers are exploring to combat muscle wasting, highlighting where GHRH analogues fit into the broader landscape.…

Continue reading

Related articles